Congress
$1,001–$15,000
Traded Dec 10, 2025 · disclosed 9 days later
8 different filers disclosed LLY within 90 days.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 24, 2025 · Filed Nov 25, 2025
A major shareholder of Eli Lilly sold $15.1M of Eli Lilly shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$15,084,973
Shares × reported transaction price
25 days after results of Oct 30, 2025, 72 days before results of Feb 4, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $1,070.16 on Nov 24, 2025, at its 52-week high, after a 31% rise over the previous 30 trading days
52-week range $625.65 (Aug 8, 2025) to $1,070.16 (Nov 24, 2025), 100% of the way up, from 250 adjusted closes. 30 trading days earlier: $819.40 on Oct 13, 2025. Describes the past only, not a forecast
RSI 84, 33% above its 200-day average, 24% above its 50-day average, at the 52-week high, 20-day volatility 26% a year, against the S&P 500: +31 points over 1 month, +42 points over 3 months, +34 points over 6 months
From the adjusted closes up to Nov 24, 2025. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Retevmo on Nov 20, 2025, 4 days before this trade.
New use approved (efficacy supplement). Active ingredient: Selpercatinib. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −6.4% | +0.6% | −7.0% |
| 30 days | −2.4% | +1.6% | −4.0% |
| 90 days | −5.6% | +1.1% | −6.8% |
| 180 days | −3.6% | +10.4% | −14.0% |
Past results only. Not a forecast.
Congress
Traded Dec 10, 2025 · disclosed 9 days later
8 different filers disclosed LLY within 90 days.
Fund moves
121 tracked managers disclosed the same change for Q3 2025. From a 13F filed Dec 18, 2025 covering holdings at Sep 30, 2025 — a quarter-end snapshot, not a live trade.
Insider filing
Traded Dec 15, 2025 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.